1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Colchicine |
| brand | String | Colcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Antigout_agents|Antigout agent]] • [[:Category:Anti-inflammatories|Anti-inflammatory]] • [[:Category:Microtubule_inhibitors|Microtubule inhibitor]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' |
| starting_dose | String | Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction |
| preparations | String | 0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco) |
| fda_max | String | 1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral (IV form withdrawn US 2009 due to fatal toxicity reports) |
| onset | String | Anti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed |
| duration | String | Hours per dose |
| halflife | String | ~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"' |
| bioavailability | String | ~45% (oral)'"`UNIQ--ref-00000C73-QINU`"' |
| pregnancy | String | Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
